MedTrace Logo

RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides

NCT00307593 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2007-11-19

No results posted yet for this study

Summary

The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.

Conditions

  • Wegener's Granulomatosis
  • Churg-Strauss Syndrome
  • Microscopic Polyangiitis

Interventions

DRUG

Infliximab

Infliximab

DRUG

Rituximab

Rituximab

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Loïc GUILLEVIN, MD, PhD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Completion
2007-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307593 on ClinicalTrials.gov